Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Teba L et al 1988 Nov USA | Case 1: 47 year old Female BP 66 mmHg Case 2: 56 year old Female BP 52 mmHg Both treated with Sodium bicarbonate and Dopmaine without significant improvement in hypotension | Case report | Systemic Systolic BP (SBP) | Case 1: Continuous infusion of norepinephrine increased SBP from 68 mmHg to >100 mmHg.Case 2: Following Norepinephrine infusion SBP increased from 52 mmHg to 130 mmHg | Only 2 case reports These may be exceptional cases |
Knudsen K, Abrahamsson J 1997 April Sweden | 91 Male Sprague-Dawley rats. All given Amitriptyline HCl infusion at@ 2mg/kg/min for 60 mins. After 5 mins given either: (a)Epinephrine infusion + 5 min bolus of sodium bicarbonate (b)Norepinephrine infusion +5 min bolus sodium bicarbonate (c)Epinephrine infusion + 5 min bolus placebo (d)Norepinephrine infusion + 5 min bolus placebo (e)Placebo infusion + 5 min bolus sodium bicarbonate (f)Placebo infusuion + 5 min bolus placebo Placebo infusion= Glucose 5% Placebo bolus= sodium chloride (9 mg/mL) 1mL/Kg/min | Non-randomised, Animal controlled intervention trial | Survival | Epinephrine+Sodium bicarbonate > survival rate than other groups (p<0.01). Epinephrine treatment groups > survival rates than Norepinephrine treatment groups (p<0.01). Treatment groups > survival rate than control groups (p<0.01). Epinephrine + Sodium bicarbonate treatment > survival rate than Epinephrine alone (p < .01). Norepinephrine + Sodium bicarbonate treatment > survival rate than Norepinephrine alone (p < .01). | Animal study hence extrapolation to humans may be difficult Not blinded Raw data unavailable in some measurments |
Arrhytmias | Epinephrine treated rats had a longer time to onset of arrythmias than Norepinephrine treated rats (21.5 Vs 11.6 mins) (p<0.05). Epinephrine+sodium bicarbonate treated rats had the longest time in sinus rhytm | ||||
QRS duration | Epinephrine treatment associated with shorter QRS interval than Norepinephrine treatment (p<0.05) | ||||
Knudsen K, Abrahamsson J Sept 1993 | 101 Male wistar rats poisoned with Amitriptyline Given either 0.1, 0.5 or 5.0 mg/Kg/min of Epinephrine or Norepinephrine. Control group recieved Glucose infusion | Non-Randomised, Animal controlled intervention trial | Mean arterial Blood Pressure | All doses of Norepinephrine and 2 higher doses of Epinephrine increased MAP. Norepinpehrine>Epinephrine at low+intermediate doses | Animal study-difficult to apply data to humans Experiment not Blinded Raw data absent from study No significant Difference between treatmeant according to Fischer's exact test |
Mortality at 75 min(%) | Control group=75%; Norepinephrine=45%; Epinephrine=27%. At intermediate dose Epinephrine group has lowest death risk (p=0.012) | ||||
Arryhthmia | Intermediate dose: Norepinephrine>arrhythmia than Epinephrine (p<0.05) | ||||
Knudsen K, Abrahamsson J 1994 Sweden | 86 Male Wistar Rats infused with Amitriptyline HCl Treated with: Epinephrine Norepinephrine Epinephrine+Magnesium Norepinephrine+magnesium Milrinone | Nonrandomised, controlled intervention trial | Survival | Epinephrine+Norepinephrine > survival than control (P<0.001). Epinephrine>Norepinephrine survival rate | Animal study-can it be useful in humans? Not blinded Small number Raw data absent in some measurements |
Increase in QRS duration | Epinephrine significantly lower increase in QRS comapred to control + norepinephrine groups | ||||
Onset Arrhythmia | Epinephrine delayed onset of arrytmias compared to control (p<0.01) | ||||
Duration Sinus rhythm | Epinephrine>control (p<0.01). Epinephrine> Norepinephrine (p<0.05) | ||||
Vernon D et al 1991 USA | 15 Dogs infused with Amitriptyline HCL Recieved Dopamine 5,15 and 30 micrograms sequentially or Norepinephrine 0.25,0.5 and 1.0 micrograms sequentially Hemodynamic measurements after each dose. | Experimental Randomised Controlled Trial | Mean Arterial Pressure (mmHg) | All doses of norepinephrine > MAP compared to Control (p<0.05). 2 higher Dopmaine doses > MAP compared to Control (p<0.05). At highest does no significant difference between Norepinephrine and Dopamine | Animal Study Not blinded Randomisation questionable Small number Eacg catecholamine infusion given sequentially |
Cardiac Output (CO) L/min | All doses of norepinephrine > CO than Control (p<0.05). 2 higher Dopmaine doses > CO than Control (p<0.05). At highest does no significant difference between Norepinephrine and Dopamine | ||||
Peak Left Ventricular dP/dt (rate of change of LV pressure) | All doses of norepinephrine > LV dP/dt than Control (p<0.05). 2 higher Dopmaine doses > LV dP/dt than Control (p<0.05). At highest does no significant difference between Norepinephrine and Dopamine | ||||
Mixed Venous Oxygen Saturation (SVO2) | All doses of norepinephrine > SVO2 than Control (p<0.05). 2 higher Dopmaine doses > LV SVO2 than Control (p<0.05). At highest does no significant difference between Norepinephrine and Dopamine | ||||
Systemic Vascular Resistance (SVR) | All doses of norepinephrine > SVP than Control (p<0.05). At highest does no significant difference between Norepinephrine and Dopamine |